` CMMB (Chemomab Therapeutics Ltd) vs S&P 500 Comparison - Alpha Spread

CMMB
vs
S&P 500

Over the past 12 months, CMMB has underperformed S&P 500, delivering a return of -68% compared to the S&P 500's +16% growth.

Stocks Performance
CMMB vs S&P 500

Loading
CMMB
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CMMB vs S&P 500

Performance Gap Between CMMB and GSPC
HIDDEN
Show

Performance By Year
CMMB vs S&P 500

Loading
CMMB
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Chemomab Therapeutics Ltd vs Peers

S&P 500
CMMB
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Chemomab Therapeutics Ltd
Glance View

Market Cap
11m USD
Industry
Biotechnology

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

CMMB Intrinsic Value
HIDDEN
Show
Back to Top